Tailoring or personalizing first dose of BU with due consideration of demographics and genotypes of GSTA1 and M1 genes could possibly help in achieving better clinical outcomes in pediatric HSCT. A model for the dosage adjustment with the inclusion of genetic and nongenetic factors shall be developed and evaluated in prospective validation cohorts to establish its utility in routine pediatric HSCT centers.
The authors are thankful to all patients and their parents who consented to participate in the genetics study. The authors also thank the Swiss Oncology Group (SPOG) as our sponsor and the European Blood and Marrow Transplantation Pediatric (EBMT) working disease group for their support and for labeling the study as an EBMT trial (NCT01257854). The authors also thank Chakradhara Rao S Uppugunduri for his critical remarks and inputs on this manuscript.
Financial & competing interests disclosure
This work was supported by grants provided by CANSEARCH, Dr Dubois-Ferrière Dinu Lipatti, the Hans Wilsdorf foundation and the Geneva Cancer League. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Personalized Medicine. 2014;11(5):463-466. © 2014 Future Medicine Ltd.